NCT03145025 is a clinical trial of Retisert in Uveitis, Posterior, sponsored by Bausch & Lomb Incorporated.

Who is sponsoring NCT03145025?

NCT03145025 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT03145025?

Interventions in NCT03145025: Retisert, Fluocinolone Acetonide Intravitreal Implant.

What condition does NCT03145025 study?

NCT03145025 studies Uveitis, Posterior.

Is NCT03145025 still recruiting?

NCT03145025 is currently completed. Last updated 21 June 2019.

Last reviewed 2019-06-21 · How we verify

NCT03145025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Completed Last updated 21 June 2019

What this trial tests

trial testing Retisert in Uveitis, Posterior in 3 participants. Completed in 22 March 2019.

Timeline

14 July 2017

Primary endpoint
10 September 2018

22 March 2019

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3
Start date	14 July 2017
Primary completion	10 September 2018
Estimated completion	22 March 2019
Sites	1 location across United States

Drugs / interventions tested

Retisert
Fluocinolone Acetonide Intravitreal Implant — full drug profile →

Conditions studied

Uveitis, Posterior — all drugs for Uveitis, Posterior →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

Adults 12 to 80, any sex, with Uveitis, Posterior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Uveitis, Posterior

Currently open trials in the same condition.

NCT06431373 — A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis · Phase 3 · active not recruiting

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03145025 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 21 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03145025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing